Opioids
USF Health studies suggest new opioid-receptor signaling step could guide development of safer painkillers
Von KI berichtet Bild generiert von KI Fakten geprüft
Researchers at USF Health report evidence that an early step in mu opioid receptor signaling can run in reverse, and that certain experimental compounds can enhance morphine- and fentanyl-driven pain relief in lab tests without increasing respiratory suppression at very low doses. The findings, published Dec. 17 in Nature and Nature Communications, are framed as a blueprint for designing longer-lasting opioids with fewer risks, though the newly tested molecules are not considered clinical drug candidates.
A comprehensive review of clinical trials indicates that tramadol, a widely prescribed opioid for chronic pain, offers only slight relief that may not be noticeable to many patients. However, it significantly increases the risk of serious side effects, particularly heart-related issues. Researchers recommend minimizing its use due to these concerns.
Von KI berichtet
ARMR Sciences, a New York-based company, is launching the first major test of a vaccine designed to protect against fentanyl overdoses. The trial will take place in the Netherlands. This development aims to address the dangers of the synthetic opioid, which can be lethal in tiny amounts.